Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

X
Trial Profile

225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Actinium-225-satoreotide-Ariceum-Therapeutics (Primary)
  • Indications Merkel cell carcinoma; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SANTANA-225
  • Most Recent Events

    • 27 Jan 2025 New trial record
    • 14 Jan 2025 According to an Ariceum Therapeutics media release, the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial ('SANTANA-225') of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). Ariceum is working with its partners and clinical sites in the US and other countries to commence recruitment of patients in Q1 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top